Table 4.

Outcomes of Participants (n=190) with Indeterminate Etiology

	Adducts Positive n=21	Adducts Negative n=169	P
	n(%)	n(%)
Hepatic Encephalopathy at Enrollment*			<0.0001
Grade II or less	12(63)	154(93)
Grade III or IV	7(37)	12(7)
Maximum Hepatic Encephalopathy**			0.10
Grade II or less	12(60)	126(77)
Grade III or IV	8(40)	38(23)
Laboratory Value Median (Q1 – Q3)
Alanine Aminotransferase IU/L	4619(3615–6871)	1604(726–2796)	<0.0001
Aspartate Aminotransferase IU/L	3689(2305–7146)	1785(713–3088)	0.0004
Total Bilirubin mg/dL	3.6(2.7–4.5)	15.2(8.7–20.2)	<0.0001
Direct Bilirubin mg/dL	1.9(0.8–2.4)	10.5(4.9–14.4)	<0.0001
International Normalized Ratio	3.7(2.4–4.4)	2.7(2.1–4.0)	0.17
Creatinine mg/dL	0.7(0.5–1.1)	0.4(0.3–0.7)	0.0043
21 day Outcome			0.03
Death without Transplantation	1(5)	18(11)
Transplantation	4(19)	76(45)
Spontaneous Survival	16(76)	75(44)

^*2 participants in adduct positive group and 3 participants in negative group with missing data

^**1 participants in adduct positive group and 5 in adduct negative group with missing data